Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4(3H)-one schiff bases
详细信息    查看全文
文摘
Development of multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB) has been considered as major health burden, globally. In order to develop novel, potential molecules against drug resistant TB, twenty two (22) new 3-substituted-7-benzyl-5,6,7,8-tetrahydropyrido[4&prime;,3&prime;:4,5]thieno[2,3-<em>dem>]pyrimidin-4(<em>3Hem>)-one (6ak) and 3-substituted-7-benzyl-2-methyl-5,6,7,8-tetrahydropyrido[4&prime;,3&prime;:4,5]thieno[2,3-<em>dem>]pyrimidin-4(<em>3Hem>)-one (7ak) derivatives were designed and synthesized by using appropriate synthetic protocols. Pantothenate synthetase (PS) was considered as the target for the molecular docking studies and evaluated the binding pattern at active site, as PS plays a significant role in the biosynthesis of pantothenate in <em>Mycobacterium tuberculosisem> (MTB). The preliminary in vitro antibacterial screening of test compounds was carried out against two strains of Gram-positive (<em>Bacillus subtilisem> and <em>Staphylococcus aureusem>) and Gram-negative (<em>Escherichia coliem> and <em>Klebsiella pneumoniaeem>) bacteria. The antimycobacterial screening was performed against MTB H37Rv and an isoniazid-resistant clinical isolate of MTB<em>.em> The compounds 6b, 6c, 6d, 6k, 7b, 7c, 7d and 7k exhibited promising antibacterial activity MIC in the range of 15–73 μM against all bacterial strains used and compounds 6d and 7b showed antimycobacterial activity (IC50 <340 μM in LRP assay) and (MIC <9 μM in broth microdilution method).

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700